Leslie Harrold to Adalimumab
This is a "connection" page, showing publications Leslie Harrold has written about Adalimumab.
Connection Strength
1.017
-
Harrold LR, Stolshek BS, Rebello S, Collier DH, Mutebi A, Wade SW, Malley W, Greenberg JD, Etzel CJ. Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease Activity. J Rheumatol. 2018 01; 45(1):78-82.
Score: 0.575
-
Harrold LR, Griffith J, Zueger P, Litman HJ, Gershenson B, Islam SS, Barr CJ, Guo D, Fay J, Greenberg JD. Longterm, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-based Registry. J Rheumatol. 2020 07 01; 47(7):959-967.
Score: 0.163
-
Navarro-Mill?n I, Herrinton LJ, Chen L, Harrold L, Liu L, Curtis JR. Comparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related Tolerability. PLoS One. 2016; 11(3):e0149781.
Score: 0.129
-
Harrold LR, Peterson D, Beard AJ, Gurwitz JH, Briesacher BA. Time trends in medication use and expenditures in older patients with rheumatoid arthritis. Am J Med. 2012 Sep; 125(9):937.e9-15.
Score: 0.100
-
Herrinton LJ, Liu L, Chen L, Harrold LR, Raebel MA, Curtis JR, Griffin MR, Solomon DH, Saag KG, Lewis JD. Association between anti-TNF-a therapy and all-cause mortality. Pharmacoepidemiol Drug Saf. 2012 Dec; 21(12):1311-20.
Score: 0.025
-
Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, Dehoratius R, Kishimoto M, Kremer JM. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis. 2012 Jul; 71(7):1134-42.
Score: 0.024